[Cancer therapy using bispecific antibodies]

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Bispecific antibodies possess two antigen-binding sites, enabling dual targeting.
• Blinatumomab, a bispecific T-cell engager (BiTE), targets CD19 on B tumor cells and CD3 on T cells, inducing tumor cell killing.
• Blinatumomab is FDA-approved for specific types of B-cell acute lymphoblastic leukemia (ALL).

Purpose of the Study:

• To review the development and therapeutic potential of bispecific antibodies.
• To highlight the mechanism of action for bispecific T-cell engagers (BiTEs).
• To discuss the expanding landscape of bispecific antibody applications in hematological malignancies.

Main Methods:

• Review of existing literature on bispecific antibodies and their clinical applications.
• Analysis of the mechanism of action of blinatumomab as a representative BiTE.
• Discussion of ongoing research and development in bispecific antibody technology.

Main Results:

• Blinatumomab effectively treats specific B-cell acute lymphoblastic leukemia (ALL) subtypes.
• Various bispecific antibody formats are under investigation, targeting different antigens and cellular compartments.
• Fc-containing bispecific antibodies offer enhanced T-cell activation and prolonged half-life.

Conclusions:

• Bispecific antibodies, including BiTEs, represent a promising therapeutic strategy for hematological malignancies.
• Ongoing advancements in bispecific antibody design are expanding treatment possibilities.
• The development of off-the-shelf bispecific antibodies could revolutionize cancer therapy.